"New Treatments May Boost Pancreatic Cancer Odds" - Dennis Thompson
Innovative ways of using chemotherapy can significantly extend the lives of patients with pancreatic cancer, one of the most deadly cancers known, two new clinical trials report. A four-drug chemo "cocktail" extended surgical patients' lives by nearly two years over the current standard single-drug chemo regimen for pancreatic cancer; a clinical trial out of France has shown. "You take overall survival from just under three years to almost five years," said Daniel Labow, MD, professor of surgery, chief of surgical oncology at the Icahn School of Medicine at Mount Sinai and site chair of the department of surgery at Mount Sinai St. Luke’s and Mount Sinai West. “That, for pancreas cancer, is a relative home run because survival in general is so poor.” Removing the pancreatic tumor using surgery is essential for long-term survival, but the patient still faces a tough road, said Dr. Labow, who wasn't involved in the studies.
- Daniel M. Labow, MD, Professor, Surgery, Chief, Surgical Oncology, Hepatobiliary Surgery, Icahn School of Medicine at Mount Sinai, Site Chair, Department of Surgery, Mount Sinai St. Luke’s, Mount Sinai West
Additional coverage:
Medscape
U.S. News & World Report
Doctors Lounge
Future Breast Imaging and Biopsy Are Not Eliminated After Mastectomy
Oct 09, 2018 View All Press Releases